[Role of the intensive care in treatment of patients with acute myeloid leukemia].

Autor:	Bazhenov AV; National Research Center for Hematology., Galstyan GM; National Research Center for Hematology., Parovichnikova EN; National Research Center for Hematology., Troitskaya VV; National Research Center for Hematology., Kuzmina LA; National Research Center for Hematology., Fidarova ZT; National Research Center for Hematology., Gribanova EO; National Research Center for Hematology., Makhinya SA; National Research Center for Hematology., Latyshkevich OA; Center of Family Planning and Reproduction., Chabaeva UA; National Research Center for Hematology., Kulikov SM; National Research Center for Hematology., Savchenko VG; National Research Center for Hematology.
Jazyk:	ruština
Zdroj:	Terapevticheskii arkhiv [Ter Arkh] 2019 Jul 15; Vol. 91 (7), pp. 14-24. Date of Electronic Publication: 2019 Jul 15.
DOI:	10.26442/00403660.2019.07.000321
Abstrakt:	Aim: Remission induction can be associate, with the life threatening complications and transfer to ICU of de novo acute myeloid leukemia (AML) patients (pts). We evaluate influence of transfer to ICU and life threatening complication on early mortality and long - tram survival of de novo AML pts. Materials and Methods: Retrospective study. All de novo AML pts younger than 60 years old admitted in the National Research Center for Hematology from 2013 to 2016 years were enrolled in the study. Patients were divided into 2 groups: pts who were required ICU admission during remission induction (ICU-pts) and pts who did not require ICU admission and received chemotherapy only in hematology ward (non-ICU pts). The reasons for ICU admissions and results of life support were analyzed. Overall survival (OS) were assessed by the Kaplan-Meier method, long rank value p.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu